SCHEMBL14830506

SCHEMBL14830506

O=C1C(=O)N(c2ccccc2)c2cccc(OC(F)(F)F)c21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.47
ALDH1A1 P00352 1/20 0.47
BCHE P06276 1/20 0.47
GAA P10253 1/20 0.47
CES1 P23141 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
GALR3 O60755 1/20 0.38
HTR4 Q13639 1/20 0.38
HCAR1 Q9BXC0 4/20 0.38
SCN9A Q15858 4/20 0.36
SCN10A Q9Y5Y9 1/20 0.35
BRD4 O60885 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAB1 Q9Y478 1/20 0.35
TOP2A P11388 1/20 0.35
HSPA1A P0DMV8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5703450 0.72 ALDH1A1 (0.56) CES2ALDH1A1BCHEGAACES1
SCHEMBL14830556 0.72 NPSR1 (0.56) CES2ALDH1A1BCHEGAACES1
SCHEMBL1901735 0.71 ALDH1A1 (0.64) CES2ALDH1A1BCHEGAACES1
SCHEMBL14830505 0.70 NPSR1 (0.61) CES2ALDH1A1BCHEGAACES1
SCHEMBL28339973 0.69 L3MBTL1 (0.54) CES2ALDH1A1BCHEGAACES1
SCHEMBL31579777 0.68 MEN1 (0.51) HTR2AHTR2CHTR2BHCAR1SCN9A
SCHEMBL6920783 0.67 GALR3 (0.44) CES2ALDH1A1BCHEGAACES1
Phenyl Isatin SCHEMBL916808 0.66 CES1 (1.00) CES2ALDH1A1BCHEGAACES1
SCHEMBL3910501 0.65 GAA (0.50) CES2ALDH1A1BCHEGAACES1
SCHEMBL11667821 0.65 HCAR1 (0.42) HCAR1KMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760840-B1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-04-16 US disclosed
US-8946430-B2 Quinolinone carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-02-03 US disclosed
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY 2014-08-28 US disclosed
EP-2760840-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE Bristol-Myers Squibb Company (US) 2014-08-06 EP disclosed
WO-2013048942-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL CES2 10/4885ALDH1A1 440/4885BCHE 199/4885
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL CES2 10/4885ALDH1A1 440/4885BCHE 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.